AcelRx Pharmaceuticals Inc  

(Public, NASDAQ:ACRX)   Watch this stock  
Find more results for ACRX
+0.08 (2.31%)
Real-time:   9:57AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.51 - 3.64
52 week 2.92 - 9.32
Open 3.51
Vol / Avg. 17,901.00/593,603.00
Mkt cap 157.53M
P/E     -
Div/yield     -
EPS -0.73
Shares 44.37M
Beta     -
Inst. own 74%
Nov 9, 2015
Q3 2015 AcelRx Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Oct 2, 2015
AcelRx Pharmaceuticals Inc Analyst & Investor Day - Webcast
Sep 29, 2015
AcelRx Pharmaceuticals Inc at Sachs Associates Biotech in Europe Investor Forum
Sep 15, 2015
AcelRx Pharmaceuticals Inc at EBD Group BioPharm America
Sep 10, 2015
AcelRx Pharmaceuticals Inc at BioCentury NewsMakers in the Biotech Industry Conference
Sep 9, 2015
AcelRx Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference - Webcast
Aug 3, 2015
Q2 2015 AcelRx Pharmaceuticals Inc Earnings Call - Webcast
Aug 3, 2015
Q2 2015 AcelRx Pharmaceuticals Inc Earnings Release
Jul 24, 2015
AcelRx Pharmaceuticals Inc Annual Shareholders Meeting (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -462.37% -639.31%
Operating margin -422.19% -721.66%
EBITD margin - -705.06%
Return on average assets -51.28% -33.95%
Return on average equity -95.82% -55.67%
Employees 50 -
CDP Score - -


351 Galveston Drive
United States - Map
+1-650-2163500 (Phone)
+1-650-2166500 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


AcelRx Pharmaceuticals, Inc. is a development-stage specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute pain. The Company's lead product candidate, Zalviso, is intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of sufentanil sublingual tablets delivered by the Zalviso System. The Company has three additional product candidates in clinical development: the Sufentanil Sublingual Tablet BTP Management System (ARX-02), a pain management system for the treatment of cancer patients who suffer from Breakthrough Pain (BTP); the Sufentanil/Triazolam Sublingual Tablet (ARX-03), is a single, fixed-dose, combination drug product designed to provide mild sedation, anxiety reduction and pain relief, and Sufentanil Sublingual Single-Dose Acute Pain Tablet (ARX-04) for the treatment of moderate-to-severe acute pain.

Officers and directors

Adrian Adams Independent Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Richard A. King President
Age: 49
Bio & Compensation  - Reuters
Howard B. Rosen Interim Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Timothy E. Morris Chief Financial Officer, Principal Accounting Officer
Age: 53
Bio & Compensation  - Reuters
Pamela P. Palmer M.D. Ph.D. Chief Medical Officer, Director
Age: 52
Bio & Compensation  - Reuters
Badri N. Dasu Chief Engineering Officer
Age: 52
Bio & Compensation  - Reuters
Lawrence G. Hamel Chief Development Officer
Age: 63
Bio & Compensation  - Reuters
Jane Wright-Mitchell Chief Legal Officer
Age: 46
Bio & Compensation  - Reuters
Richard F. Afable M.D. Director
Age: 61
Bio & Compensation  - Reuters
Mark G. Edwards Independent Director
Age: 57
Bio & Compensation  - Reuters